Stocks
J&J Share Price Soars as New Drugs Drive Growth
Johnson & Johnson's (JNJ) share price has surged 55.5% over the past year, outperforming the S&P 500's 20.7% return.
This strong performance is attributed to the company's focus on advancing its pharmaceutical segment and recent FDA approvals.
The decision to spin off its healthcare division, Kenvue, in May 2023 has allowed J&J to concentrate on developing new drugs.
One of these newer treatments, Icotyde, is showing promise with a projected sales target of $2.4 billion by 2028.